Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Other Non Operating Income (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Non Operating Income for 15 consecutive years, with -$8.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 373.34% to -$8.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.1 million, a 167.59% decrease, with the full-year FY2025 number at -$1.7 million, down 186.7% from a year prior.
  • Other Non Operating Income was -$8.2 million for Q4 2025 at Aytu Biopharma, down from $3.8 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.6 million in Q4 2023 to a low of -$8.2 million in Q4 2025.
  • A 5-year average of $161789.5 and a median of $13000.0 in 2022 define the central range for Other Non Operating Income.
  • Biggest YoY gain for Other Non Operating Income was 636.4% in 2023; the steepest drop was 9446.15% in 2023.
  • Aytu Biopharma's Other Non Operating Income stood at -$257000.0 in 2021, then tumbled by 377.82% to -$1.2 million in 2022, then soared by 636.4% to $6.6 million in 2023, then tumbled by 54.21% to $3.0 million in 2024, then crashed by 373.34% to -$8.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Non Operating Income are -$8.2 million (Q4 2025), $3.8 million (Q3 2025), and $1.3 million (Q2 2025).